Although the application of MEK inhibitors has been discussed for several conditions, the literature is devoid of a unifying review of MEK inhibitors and their therapeutic strategies for malignant conditions of the CNS, specifically that of glioblastoma. The gene discussed is MAP2K7; the disease is glioblastoma.